Maverick Therapeutics Inc. logo

Maverick Therapeutics Inc.

Maverick Therapeutics, (spun out of Harpoon Therapeutics) is a preclinical stage biotech company, developing a novel class of T cell- redirecting antibody therapeutics that have the potential to substantially broaden the range of targets and clinical applications to be used for this ultra-potent mechanism.

Maverick is a MPM Capital portfolio company. Hans-Peter Gerber, whose experience includes executive roles in Pfizers oncology research unit, lead Maverick as the companys president and chief scientific officer. Immediately prior to joining Maverick, Gerber had been chief scientific officer of Harpoon.

0
Management
0
Technology
0
Deals/Partnering
0
Research Pipeline
0
Funding
BioStartup's Score 0 / 50

KEY DETAILS

Websitehttps://www.mavericktx.com
Founded2016
Disease Focus
Development Stage
STOCK CODENon Listed
Address
3260 B Bayshore Blvd.,CA,94005
Brisbane
United States
Email
Contact Number
+1650 338 1231

[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=” ” connections=”true” suffix=””]

Mavericks approach is based on the T-cell engagement in the tumor microenvironment, which allows to address previously intractable oncology targets Critical to the opportunity. Mavericks antibodies are designed to extend the therapeutic index via their selective activation in the tumor microenvironment.

In Jan 2017, Maverick and Takeda Pharmaceutical entered a collaboration to co-develop Mavericks T-cell engagement platform created specifically to improve the utility of T-cell redirection therapy for the treatment of cancer. Under the terms, Takeda will provide a $125 million of funding, which includes an upfront option, equity and research and development funding payments, and provides Takeda the exclusive right to purchase Maverick after five years for an undisclosed sum.

In Jan 2017, Maverick Therapeutics raised $23 million in a series B financing from founding investor MPM Capital and Takeda Pharmaceutical Co. Ltd.